Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Glioblastoma

Glioblastoma

Part of Glioma

23 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Glioblastoma

115 trials tracked for Glioblastoma: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 2784 citations.

115Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 76 Phase 1 17 Other / NA 12
  1. Phase 3 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed · 2,784 cited
  2. Phase 3 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Completed · 1,437 cited
  3. Phase 3 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Completed · 111 cited
  4. Phase 3 Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Completed · 40 cited
  5. Phase 4 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed
  6. Phase 3 A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy Completed
Show 44 more trials
  1. Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed
  2. Phase 3 Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Completed
  3. Phase 3 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed
  4. Phase 3 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed
  5. Phase 2 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed
  6. Phase 2 Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas Completed
  7. Phase 2 Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. Completed
  8. Phase 2 Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. Completed
  9. Phase 2 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Completed
  10. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  11. Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Completed
  12. Phase 2 HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma Completed
  13. Phase 2 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma Completed
  14. Phase 2 Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas Completed
  15. Phase 2 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Completed
  16. Phase 2 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed
  17. Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
  18. Phase 2 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed
  19. Phase 2 Dose-Intense Temozolomide in Recurrent Glioblastoma Completed
  20. Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed
  21. Phase 2 Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma Completed
  22. Phase 2 Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma Completed
  23. Phase 2 Bevacizumab Beyond Progression (BBP) Completed
  24. Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Completed
  25. Phase 2 Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma Completed
  26. Phase 2 Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Completed
  27. Phase 2 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed
  28. Phase 2 Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Completed
  29. Phase 2 Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors Completed
  30. Phase 2 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed
  31. Phase 2 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma Completed
  32. Phase 2 A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma Completed
  33. Phase 2 Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Completed
  34. Phase 2 Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Completed
  35. Phase 2 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Completed
  36. Phase 2 Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Completed
  37. Phase 2 A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma Completed
  38. Phase 2 Ph II Bevacizumab + Etoposide for Pts w Recurrent MG Completed
  39. Phase 2 Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Completed
  40. Phase 2 Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma Completed
  41. Phase 2 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma Completed
  42. Phase 2 BIBF 1120 for Recurrent High-Grade Gliomas Completed
  43. Phase 2 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Completed
  44. Phase 2 Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma Completed

Showing the 50 most-cited and recently-updated of 115 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
Allergy & Immunology Sys. Review
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
Frontiers Jun 15, 2026
Dysregulation of the TOX/TCF-1 axis and IDH-mutation driven silencing drive cytotoxic failure in glioblastoma
Allergy & Immunology Sys. Review
Dysregulation of the TOX/TCF-1 axis and IDH-mutation driven silencing drive cytotoxic failure in glioblastoma Single-cell atlas reveals how glioblastoma disables immune cells
This systematic review examines the immunological landscape of glioblastoma, specifically focusing on cytotoxic lymphocyte dysfunction. The …
A systematic review maps the cellular and molecular mechanisms behind immune failure in glioblastoma, identifying key targets for future the…
Frontiers Jun 10, 2026
Meta-analysis links high platelet ratios to worse overall survival in adult glioblastoma patients
Oncology Meta-analysis
Meta-analysis links high platelet ratios to worse overall survival in adult glioblastoma patients High blood cell ratios linked to shorter life in glioblastoma patients
This meta-analysis reviews data from 2609 patients with WHO grade 4 diffuse astrocytoma to evaluate platelet indices. High platelet: lymphoc…
High blood cell ratios are linked to shorter life in glioblastoma patients. This analysis of over 5,000 adults shows how simple blood tests …
May 23, 2026
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
Pulmonology & Critical Care Sys. Review
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Frontiers May 16, 2026
Review of glioma organoid models for mechanistic discovery and therapy development
Oncology Sys. Review
Review of glioma organoid models for mechanistic discovery and therapy development Finally Lab-Grown Brain Models Could Speed Up Glioma Treatments
This narrative review summarizes glioma organoid model systems for studying tumor-neural interactions. It concludes these models provide a f…
• Tiny lab-grown brains mimic real tumor behavior better than old methods • Kids and adults fighting deadly brain cancers like glioblastoma …
Frontiers May 15, 2026
Tumor treating fields plus chemotherapy improved survival outcomes for newly diagnosed and recurrent glioblastoma patients in this meta-analysis
Rheumatology Meta-analysis
Tumor treating fields plus chemotherapy improved survival outcomes for newly diagnosed and recurrent glioblastoma patients in this meta-analysis Brain Cancer Survival Jumps When Adding This Therapy to Chemo
A systematic review and meta-analysis of 2,376 patients found that adding tumor treating fields to chemotherapy significantly prolonged prog…
Adding a wearable electric field device to standard chemotherapy helps glioblastoma patients live significantly longer with similar major si…
Frontiers May 8, 2026
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
Oncology Sys. Review
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Frontiers May 5, 2026
Meta-analysis of preclinical models shows enhanced outcomes for focused ultrasound gene therapy in glioblastoma
Genetics & Precision Medicine Meta-analysis
Meta-analysis of preclinical models shows enhanced outcomes for focused ultrasound gene therapy in glioblastoma Ultrasound Opens a New Door for Brain Cancer Treatment
This systematic review and meta-analysis evaluated focused ultrasound mediated gene therapy in preclinical orthotopic glioblastoma in vivo m…
A new review of nine studies shows that focused ultrasound can safely deliver gene therapy across the brain's protective barrier, shrinking …
May 4, 2026
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Oncology Meta-analysis
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
May 1, 2026
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Genetics & Precision Medicine Phase I
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
May 1, 2026
Specialized palliative care intervention enrollment patterns in a glioblastoma randomized controlled trial sub-analysis
Oncology RCT
Specialized palliative care intervention enrollment patterns in a glioblastoma randomized controlled trial sub-analysis Glioblastoma trial reveals why patients skip or delay visits
This sub-analysis of the Early Palliative Care for Patients with Glioblastoma (EPCOG) trial examined enrollment and retention among 556 scre…
Many glioblastoma patients skip or delay study visits due to illness or lack of interest, a new trial analysis finds.
Apr 27, 2026
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results
Oncology Phase I
LP-184 Alone and With Spironolactone in Recurrent Glioblastoma: Phase 1a Results New drug combo may help brain cancer patients who have run out of options
This Phase 1a trial in 63 patients (16 with glioblastoma) found LP-184 was well tolerated but with more transaminitis and thrombocytopenia i…
A new drug combination could help brain cancer patients by making their current medicine work much harder inside the tumor.
medRxiv Apr 25, 2026

Research across Glioma

Related studies from across the Glioma family.

PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme
Oncology Cohort
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme A Simple Brain Tumor Test Could Predict Your Treatment Path
This prospective observational cohort study evaluated PINK1 expression in adults (18+ years) with newly diagnosed IDH-wild type glioblastoma…
A specific protein in glioblastoma tissue could forecast survival odds, helping patients plan care even though the test is not available yet…
medRxiv Apr 10, 2026

Questions about Glioblastoma

Can focused ultrasound gene therapy improve outcomes for glioblastoma based on preclinical studies?

Yes, preclinical studies show focused ultrasound gene therapy significantly enhances gene expression, reduces tumor volume, and improves survival in glioblastoma animal models.

Full answer →
Did adding tumor treating fields to chemotherapy help newly diagnosed glioblastoma patients live longer?

Yes, adding tumor treating fields (TTFields) to chemotherapy significantly improved overall survival and progression-free survival in newly diagnosed glioblastoma patients, according to a meta-analysis and clinical studies.

Full answer →

All Glioblastoma Articles